Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI-Platinum Therapy (WJOG14120L). (PubMed, Cancer Sci) - Oct 1, 2026 - "CGN may be a feasible treatment option for second-line after ICI-based therapy, including for patients unsuitable for anti-angiogenic therapies, although further validation is warranted. Trial Registration: jRCTs051200138."
Journal • P2 data • Hematological Disorders • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Pneumonia • Solid Tumor • Squamous Cell Carcinoma
|
|
Haruko Daga; Hiroaki Akamatsu; Hiroaki Kanemura; Hiroshi Handa; Hiroshige Yoshioka; Kazuhiko Nakagawa; Keita Mori; Koichi Azuma; Masafumi Yamaguchi; Nobuhisa Ishikawa; Nobuyuki Yamamoto; Takayasu Kurata; Teppei Yamaguchi; Yosuke Tamura; Yuki Sato; Yukihiro Toi
|